2. Search Result
Search Result
Results for "

myostatin

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

4

Peptides

7

Inhibitory Antibodies

1

Natural
Products

11

Recombinant Proteins

1

Antibodies

2

Oligonucleotides

Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-P99388
    Trevogrumab
    1 Publications Verification

    REGN-1033; SAR391786

    		 TGF-beta/Smad Metabolic Disease
    Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as myostatin). Trevogrumab is used in research on muscle wasting conditions, including disuse atrophy, chronic diseases, and changes in food and nutrient intake .
    Trevogrumab
  • HY-P99518
    Taldefgrobep alfa

    BMS 986089; RG 6206; RO 7239361; BHV2000

    		 TGF-beta/Smad Others
    Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a protein that blocks myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research .
    Taldefgrobep alfa
  • HY-132611
    Golodirsen

    SRP-4053

    		 Dystrophin DNA/RNA Synthesis Neurological Disease
    Golodirsen (SRP-4053) is an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO). Golodirsen restores the reading frame of the Duchenne muscular dystrophy (DMD) gene by modifying the splicing process of the pre-mRNA, skipping exon 53. Golodirsen can restore the expression of the anti-myostatin protein. Golodirsen can be used for the research of duchenne muscular dystrophy (DMD) .
    Golodirsen
  • HY-P99370
    Landogrozumab
    1 Publications Verification

    LY2495655; Anti-GDF8 / myostatin Reference Antibody (landogrozumab)

    		 TGF-beta/Smad Inflammation/Immunology Cancer
    Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease .
    Landogrozumab
  • HY-P10476
    Myostatin inhibitory peptide 2

    		TGF-beta/Smad Others
    Myostatin inhibitory peptide 2 (compd 2) is a myostatin inhibitor with a Kd of 35.9 nM. Myostatin inhibitory peptide 2 can be used for researches of muscle atrophic disorders .
    Myostatin inhibitory peptide 2
  • HY-P990993
    Emugrobart

    GYM-329, RG6237, RG-70240

    		 TGF-beta/Smad Inflammation/Immunology
    Emugrobart (GYM-329, RG6237, RG-70240) is a humanized IgG1κ antibody targeting myostatin (Myostatin; GDF8). Emugrobart binds to pro-myostatin and latent myostatin, blocking their cleavage into mature myostatin; it also has a clearance function, which transports bound myostatin for degradation and allows for cyclic reuse. Emugrobart enhances muscle strength in mouse models of muscle atrophy and increases muscle mass in cynomolgus monkeys. Emugrobart can be used in research on spinal muscular atrophy and facioscapulohumeral muscular dystrophy .
    Emugrobart
  • HY-P99857
    Domagrozumab

    PF-06252616

    		 TGF-beta/Smad Metabolic Disease
    Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
    Domagrozumab
  • HY-P10242
    Myostatin inhibitory peptide 7

    		TGF-beta/Smad Others
    Myostatin inhibitory peptide 7 is a 23 amino acids peptide, which is derived from amino acids 21 to 43 of the mouse myostatin prodomain. Myostatin inhibitory peptide 7 inhibits myostatin with a Kd of 29.7 nM. Myostatin inhibitory peptide 7 can be used for researches of muscle atrophic disorders .
    Myostatin inhibitory peptide 7
  • HY-P99588
    Stamulumab
    1 Publications Verification

    MYO-029

    		 TGF-β Receptor Metabolic Disease
    Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
    Stamulumab
  • HY-130687A
    Psicose

    DL-Psicose

    		 PI3K mTOR Akt IGF-1R TGF-beta/Smad Mitochondrial Metabolism Neurological Disease Metabolic Disease
    Psicose (DL-Psicose) is an orally effective sugar substitute. Psicose activates the PI3K/Akt/mTOR pathway to promote muscle synthesis. Psicose upregulates IGF-1 and downregulates Myostatin. Psicose normalizes mitochondrial dysfunction by increasing G6P activity. Psicose enhances the activity of antioxidant enzymes and reduces oxidative stress markers. Psicose increases muscle mass, grip strength and muscle weight in aged mice and diet-induced obese mice. Psicose improves obesity and type 2 diabetes. Psicose can be used in the research of age-related sarcopenia .
    Psicose
  • HY-132611A
    Golodirsen sodium

    SRP-4053 sodium

    		 DNA/RNA Synthesis Dystrophin Neurological Disease
    Golodirsen (SRP-4053) sodium is an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO). Golodirsen sodium restores the reading frame of the Duchenne muscular dystrophy (DMD) gene by modifying the splicing process of the pre-mRNA, skipping exon 53. Golodirsen sodium can restore the expression of the anti-myostatin protein. Golodirsen sodium can be used for the research of duchenne muscular dystrophy (DMD) .
    Golodirsen sodium
  • HY-112821
    IBS008738
    3 Publications Verification

    		 YAP Inflammation/Immunology
    IBS008738 is a potent TAZ activator. IBS008738 stabilizes TAZ, increases the unphosphorylated TAZ level, enhances the association of MyoD with the myogenin promoter, upregulates MyoD-dependent gene transcription, and competes with myostatin in C2C12 cells. IBS008738 enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model .
    IBS008738
  • HY-P10242A
    Myostatin inhibitory peptide 7 TFA

    		TGF-beta/Smad Others
    Myostatin inhibitory peptide 7 TFA is a 23 amino acids peptide, which is derived from amino acids 21 to 43 of the mouse myostatin prodomain. Myostatin inhibitory peptide 7 TFA inhibits myostatin with a Kd of 29.7 nM. Myostatin inhibitory peptide 7 TFA can be used for researches of muscle atrophic disorders .
    Myostatin inhibitory peptide 7 TFA
  • HY-P10476A
    Myostatin inhibitory peptide 2 TFA

    		TGF-beta/Smad Others
    Myostatin inhibitory peptide 2 (compd 2) TFA is a myostatin inhibitor with a Kd of 35.9 nM. Myostatin inhibitory peptide 2 TFA can be used for researches of muscle atrophic disorders .
    Myostatin inhibitory peptide 2 TFA
  • HY-N2457
    Laxogenin

    (25R)-3β-Hydroxy-5α-spirostan-6-one; 6-Oxotigogenin

    		 Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    Laxogenin ((25R)-3β-Hydroxy-5α-spirostan-6-one; 6-Oxotigogenin) is an orally active myostatin (myostatin) inhibitor. Laxogenin promotes myogenesis and enhances the formation and maturation of myotubes. Laxogenin downregulates ROS. When added to the culture medium for cultured meat production, Laxogenin improves the texture, quality and nutritional value of cultured meat. Laxogenin reduces the average number of tumors in a two-stage mouse lung carcinogenesis model. Laxogenin can be used in research related to myogenesis and lung cancer .
    Laxogenin

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

  

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

  

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: